. Author manuscript; available in PMC: 2022 Jun 8.

Published in final edited form as: Lancet Microbe. 2022 Apr 7;3(6):e408–e416. doi: 10.1016/S2666-5247(21)00308-6

Table 2:

Summary of pharmacokinetic measurements

	Rifampicin (n=44)	Isoniazid (n=44)	Pyrazinamide (n=38)^*	Ethambutol (n=39)^*
C _max , mg/L
Concentration	4·5 (2·6–7·4)	3·2 (2·1–5·5)	30·2 (20·2–40·5)	0·9 (0·7–1·7)
Number at target^†	8 (18%)	24 (54%)	28 (74%)	6 (15%)
AUC _0–24 , mg×hr/L
Concentration	22·7 (12·6–39·0)	13·0 (7·1–21·3)	276·0 (181·8–391·4)	9·4 (5·1–13·7)
Number at target^‡	13/37 (35%)	2/40 (5%)	11/34 (32%)	..
Dose, mg/kg	11·8 (9·2–13·9)	6·0 (4·6–7·0)	30·4 (23·5–36·5)	21·2 (16·6–25·6)

Data are n (%) or median (IQR) unless otherwise specified. C_max=peak serum concentration. AUC_0–24=area under the concentration curve from 0–24 hours.

Pyrazinamide and ethambutol were not administered in some instances at the discretion of the treating physicians.

^†

Target C_max defined as ≥8 mg/L for rifampicin, ≥3 mg/L for isoniazid, ≥20 mg/L for pyrazinamide, ≥2 mg/L for ethambutol.¹⁶

^‡

Target AUC_0–24 defined as ≥35 mg × h/L for rifampicin, ≥52 mg × h/L for isoniazid, ≥363 mg × h/L for pyrazinamide.⁴